Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus gemcitabine adjuvant regimens versus gemcitabine plus Tegafur/Gimeracil/Oteracil in resectable pancreatic cancer
ChiCTR2100049365Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2021
- Modality
- Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paclitaxel, gemcitabine and tegafur + gimeracil + oteracil in pancreatic cancer (PC) (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: 2-year disease-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
paclitaxelgemcitabinetegafur + gimeracil + oteracil
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100049365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049365.